UNSPSC 51352008: Norethindrone or norethisterone

This classification denotes a therapeutic progestin with the molecular formula C20H26O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T18F433X4S, chemically known as 19-nortestosterone, 17-ethynyl- but generally known as norethindrone, which bears US NIH Compound Identifier 4536. European Medicines Agency schedules Norethindrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09362MIG. World Health Organization schedules norethindrone in its Anatomical Therapeutic Chemical (ATC) Classification.

Norethindrone or norethisterone bears US NLM identifiers UMLS ID C0028356 and NCI Concept Code C62059. SMILES: OC1(C2(C(C3C(CC2)C2C(=CC(=O)CC2)CC3)CC1)C)C#C.

UNSPSC 51352008 Norethindrone or norethisterone is a Commodity code covering the manufacture and supply of this specific oral contraceptive active pharmaceutical ingredient and finished-form product. State and local governments procure this drug through cooperative purchasing frameworks that aggregate demand across multiple jurisdictions and healthcare facilities, including correctional institutions, public health clinics, and state Medicaid programs. Suppliers must meet stringent manufacturing standards including current Good Manufacturing Practices (cGMP) certification and Drug Supply Chain Security Act (DSCSA) compliance, maintain established relationships with authorized pharmaceutical wholesalers, and provide products with documented National Drug Codes (NDC), packaging specifications, and shelf-life assurances. The issuing bodies are primarily state-level cooperative purchasing alliances and state procurement offices acting on behalf of participating municipalities, counties, and healthcare systems within their membership.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary active buyer for this code, with recent activity spanning Minnesota and Oregon. MMCAP issued an RFP (S1070000015802) on January 20, 2026 with a response deadline of March 26, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, including products in the norethindrone category. The procurement requires vendors to supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with products available by May 15, 2026 and contracts effective July 1, 2026. Evaluation weights price competitiveness at 75 percent, with the remainder distributed across fixed pricing, administrative compliance, EDI capability, and willingness to accept a 3 percent administrative fee. The contract term is two years for new vendors with optional extensions, and vendors must carry commercial general liability insurance of $5 million per occurrence, network security and privacy liability of $2 million, and professional liability of $2 million.